Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981028 | 0.94 | PDE3B (0.32) | PDE3BPDE3APTGS1PTGS2NPC1 | |
| SCHEMBL981082 | 0.91 | HPGD (0.32) | PDE3BPDE3APTGS1PTGS2MAPT | |
| SCHEMBL23221091 | 0.90 | KDM4E (0.33) | PDE3BPDE3APTGS1PTGS2MAPT | |
| SCHEMBL1864604 | 0.88 | RECQL (0.34) | PDE3BPDE3APTGS1PTGS2MAPT | |
| SCHEMBL1612165 | 0.87 | GABRP (0.35) | PDE3BPDE3APTGS1PTGS2MAPT | |
| SCHEMBL23784652 | 0.87 | RECQL (0.34) | PDE3BPDE3AMAPTKDM4E | |
| SCHEMBL1609805 | 0.86 | ALDH1A1 (0.35) | PDE3BPDE3ALMNAPTBP1 | |
| SCHEMBL1859165 | 0.84 | KDM4E (0.32) | PTGS1PTGS2MAPTKDM4ENPC1 | |
| SCHEMBL112624 | 0.84 | PDE3B (0.34) | PDE3BPDE3AHPGD | |
| SCHEMBL980527 | 0.84 | PDE3B (0.31) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751821-B1 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9676692-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8952175-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2172462-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND, AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | PDE3B 1249/4885PDE3A 750/4885PTGS1 749/4885 |
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | ADH1C, CYP2E1, ADH1A | PDE3B 1601/4885PDE3A 779/4885PTGS1 739/4885 |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | PDE3B 1249/4885PDE3A 750/4885PTGS1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.